Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Phenylacetylglycine is a glycine conjugate of phenylacetate.1,2,3,4 It is formed via the conversion of phenylalanine by gut microbiota to phenylacetic acid followed by glycine conjugation in the liver.1,5 Phenylacetylglycine (100 µM) decreases hypoxia-induced apoptosis in neonatal mouse cardiomyocytes.2 Levels of phenylacetylglycine in urine and plasma are increased in a rat model of phospholipidosis induced by the antiarrhythmic agent amiodarone (Item No. 15213).4 Phenylacetylglycine reduces myocardial infarct size in a mouse model of ischemia-reperfusion injury.2
WARNING This product is not for human or veterinary use.
1. A cardiovascular disease-
2. The gut microbial metabolite phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion through activating β2AR. Arch. Biochem. Biophys. 697, 108720 (2021).
3. Some observations on the urinary excretion of glycine conjugates by laboratory animals. Xenobiotica 12(6), 387-395 (1982).
4. Biomarker discovery for drug-
5. Two distinct gut microbial pathways contribute to meta-